Sparks Therapeutics' gene therapy treatment for blindness heads to FDA

7:31 AM ET Thu, 12 Oct 2017

CNBC's Meg Tirrell reports Sparks Therapeutics could be the first biotech company in the U.S. to get approval from the FDA to treat a rare form of blindness at its genetic root.